Tracking every rollback, reversal, and overreach — and the path back to the America we know.
The Trump administration redirected the Title X family planning program to de-emphasize hormonal birth control provision at health clinics. This policy shift changes the program's core focus despite clinics receiving delayed funding. The change directly impacts women's access to contraception through federally-funded clinics nationwide.
The Trump administration announced 100% tariffs on patented drugs to force pharmaceutical companies into pricing negotiations and shift manufacturing to America. This action leverages tariff threats to compel drugmakers into 'most-favored nation' pricing deals. The policy directly impacts drug prices and availability for American consumers while pressuring companies to relocate production domestically.
Executive Order 14336 directs the establishment and filling of a Strategic Active Pharmaceutical Ingredients Reserve to strengthen domestic pharmaceutical supply chains. The order aims to reduce U.S. dependence on foreign sources for critical drug components and improve resilience against supply disruptions. Americans may see increased availability and potentially lower costs for essential medications through enhanced domestic pharmaceutical production capacity.
President Trump signed Executive Order 14297 to implement Most-Favored-Nation (MFN) pricing for prescription drugs, requiring Medicare to pay no more than the lowest price paid in other developed nations. The order aims to reduce drug costs for American patients and Medicare spending by allowing the government to negotiate lower pharmaceutical prices based on international benchmarks.
Executive Order 14293 signed on May 5, 2025, removes regulatory barriers to increase domestic production of critical medicines in the United States. The order streamlines FDA approval processes and reduces compliance requirements for pharmaceutical manufacturers. This aims to reduce American dependence on foreign drug sources and lower medication costs for consumers.
President Trump signed Executive Order 14273 on April 15, 2025, implementing measures aimed at lowering prescription drug prices for American consumers. The order directs federal agencies to reduce pharmaceutical costs through regulatory reform and market mechanisms. This action is intended to decrease out-of-pocket medication expenses for Medicare, Medicaid, and privately insured Americans.
On February 25, 2025, President Trump signed Executive Order 14221 requiring healthcare providers to disclose pricing information to patients. The order directs federal agencies to establish and enforce rules for clear, accurate healthcare price disclosure. Direct effects on Americans include increased access to healthcare pricing data before receiving services, though implementation timelines and enforcement mechanisms are being developed by relevant agencies.
On February 18, 2025, President Trump signed Executive Order 14216 directing federal agencies to expand access to in vitro fertilization (IVF) services. The order instructs relevant agencies to remove regulatory barriers and increase IVF availability through federal health programs and supported facilities. The confirmed direct impact includes expanded IVF coverage eligibility and reduced administrative obstacles for Americans seeking fertility treatment through federally-supported healthcare.
Executive Order 14212 was signed on February 13, 2025, establishing the President's Make America Healthy Again Commission. The order creates a commission to develop policy recommendations related to public health and healthcare. The confirmed direct impact on Americans includes the creation of a new advisory body that will issue reports and recommendations on health policy, though implementation of any recommendations would require further action.
On January 28, 2025, President Trump signed Executive Order 14187 directing federal agencies to restrict gender-affirming medical treatments for minors under 18 years old. The order requires federal agencies to cease funding, authorization, or facilitation of puberty blockers, hormone therapy, and surgeries for transgender youth, and directs the Department of Health and Human Services to issue guidance restricting these treatments. Confirmed direct impact includes potential reduction in federal funding for medical facilities providing these treatments and changes to federal health program coverage policies affecting transgender minors seeking medical care.